Mouse pre-microRNA Expression Construct mir-208a
- Known as:
- Mouse pre-microRNA Expression Construct mir-208a
- Catalog number:
- mmir-208a-pa-1
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Sbi systeme bioscience
- Gene target:
- Mouse pre-microRNA Expression Construct mir-208a
Related genes to: Mouse pre-microRNA Expression Construct mir-208a
- Gene:
- MIR208A NIH gene
- Name:
- microRNA 208a
- Previous symbol:
- MIRN208, MIRN208A
- Synonyms:
- hsa-mir-208, hsa-mir-208a
- Chromosome:
- 14q11.2
- Locus Type:
- RNA, micro
- Date approved:
- 2004-04-23
- Date modifiied:
- 2019-01-18
Related products to: Mouse pre-microRNA Expression Construct mir-208a
Related articles to: Mouse pre-microRNA Expression Construct mir-208a
- Acute coronary syndrome (ACS) remains a leading cause of cardiovascular morbidity and mortality worldwide. High-throughput omics technologies offer opportunities for more comprehensive understanding of ACS pathophysiology. - Source: PubMed
Publication date: 2026/09/02
Sharma Yash PaulMittal AnkurSinghal KratickaN NaveenaHatwal JunialiPradhan AkshyayaSingh AshishMohan BishavBatta Akash - Cardiac contractility is regulated by two myosin heavy chain (MHC) protein isoforms, and β, encoded by the and genes. The intronic regions of these genes encode the microRNAs and , which are key regulators of cardiac hypertrophy. Functionally relevant long non-coding RNAs (lncRNAs) have also been identified at these loci, such as those transcribed in the antisense direction from the gene, including the primary transcript () originating from an internal promoter. Additionally, , another cardiac sarcomeric myosin gene, serves as a precursor for . - Source: PubMed
Publication date: 2026/08/07
Červenák ZdenkoČervenák FilipValášková SimonaChomaničová NikolaKatreničová NikoletaHulman MichalGažová AndreaKyselovic Jan - : Early diagnosis of acute myocardial infarction (AMI) remains challenging due to the "diagnostic blind window" of conventional protein biomarkers and the limited sensitivity of electrocardiograms in non ST-segment elevation myocardial infarction (NSTEMI). Cardiospecific circulating microRNAs, specifically the microRNA-208 (miR-208) family, have emerged as promising candidates to bridge this gap. This systematic review and meta-analysis evaluated the diagnostic accuracy of circulating miR-208 and outlines a proposed conceptual framework to guide its clinical translation. : PubMed and Embase were systematically searched up to June 24th, 2026, for clinical studies evaluating the diagnostic performance of circulating miR-208a and/or miR-208b against standard reference definitions for AMI. Risk-of-bias assessment using the QUADAS-2 tool was performed independently by two reviewers. Pooled sensitivity and specificity were estimated using bivariate random effects modeling, and sources of heterogeneity were explored via subgroup analyses. : Forty-one studies enrolling 6306 participants were included in the qualitative synthesis, of which 14 were eligible for meta-analysis. The pooled sensitivity and specificity of circulating miR-208 for AMI detection were 0.89 (95% CI: 0.81-0.94) and 0.90 (95% CI: 0.83-0.94), respectively. Marked between-study heterogeneity was observed. Subgroup analyses revealed significantly higher diagnostic accuracy in isolated STEMI (sensitivity: 0.95) or NSTEMI (sensitivity: 0.93) cohorts compared to mixed chest pain populations (sensitivity: 0.65; < 0.0001). Specificity dropped from 0.90 with healthy controls to 0.80 when using non-AMI controls ( = 0.002), indicating spectrum bias. Funnel plots suggested prominent small-study effects. : Circulating miR-208 exhibits a powerful biological signal for the early detection of cardiomyocyte injury, but its standalone clinical utility is constrained by methodological heterogeneity and publication bias. Rather than an immediate clinical tool, future prospective translation requires evaluating this biomarker within the standardized miAMI framework-conceptually prioritizing future investigation of the hyper-acute (<2 h) window, absolute quantification to resolve normalization variability, and integration into multi-marker point-of-care panels. - Source: PubMed
Publication date: 2026/07/13
Crabbe AugustinAntohi Andreea LauraDodi GianinaCovic AdrianAbd ElHafeez SamarPesce FrancescoNistor Ionut - Rapid and accurate diagnosis of cardiovascular disease (CVD) is essential for timely intervention, yet current workflows often rely on hospital-based instrumentation that can delay decision-making. We present SAFE (Sonication-Assisted liposome Fusion with Extracellular vesicles (EVs)), a rapid, direct-from-plasma assay that quantifies microRNAs (miRNAs) encapsulated within EVs in approximately 10 min, providing a molecular signature of myocardial injury. SAFE delivers molecular beacons (MBs) into endogenous EVs through liposome fusion, eliminating the need for EV isolation and RNA extraction while minimizing interference from plasma proteins by confining hybridization within the EV lumen. Brief sonication accelerates fusion kinetics, shortening the assay time to 10 min. In a pilot clinical evaluation involving patients with CVD (n = 20) and healthy controls (n = 15), SAFE detected elevated levels of two cardiac-associated miRNAs (miR-133a and miR-208a), achieving a diagnostic accuracy of 91.4% for each. These findings position SAFE as a rapid and minimally processed platform for the direct quantification of EV-associated miRNAs, well suited for time-critical CVD triage and ready for implementation studies across diverse clinical environments. - Source: PubMed
Publication date: 2026/06/24
Jena Subhra SuliptaKim Soo JinJang HyeonhaChi LianhuaEom YunjiDoh Kyung-OhLee JaeJongPark Jun SeokLee JunyeopHong Seonki - : Cardiomyocyte-derived small extracellular vesicles (CM-sEVs) have emerged as important mediators of intercellular communication in cardiovascular diseases (CVDs). However, their origin-tracing markers, molecular signatures, and clinical applications remain incompletely characterized and lack systematic synthesis. This systematic review aimed to comprehensively evaluate CM-sEVs-specific markers, disease-associated cargos alterations, and their roles in intercellular communication. - Source: PubMed
Publication date: 2026/05/18
Liu ShaojiaoTeng YuSu ShaWang MengWang LeiZhao Mingjing